The Gender-Biased Differential Effect of KDM6A Mutation on Immune Therapy in Urothelial Carcinoma: A Public Database Study
Authors:
- Yohei SekinoYohei Sekino
- Hikaru NakaharaHNHikaru Nakahara
- Kenichiro IkedaKIKenichiro Ikeda
- Kohei KobatakeKKKohei Kobatake
- Yuki KohadaYKYuki Kohada
- Ryo TasakaRTRyo Tasaka
- Kenshiro TakemotoKTKenshiro Takemoto
- Shunsuke MiyamotoSMShunsuke Miyamoto
- Hiroyuki KitanoHKHiroyuki Kitano
- Keisuke GotoKGKeisuke Goto
- Akihiro GorikiAGAkihiro Goriki
- Keisuke HiedaKHKeisuke Hieda
Open Access
Abstract
Background/Objectives: It is said that genes that escape from X chromosome inactivation (XCI) contribute to gender differences. We analyzed the prognostic role of these genes and identified a gender-biased difference in prognosis according to KDM6A mutation in the immune therapy cohort (IMvigor 210). We also investigate the gender-biased differential effect of KDM6A mutation in several public databases of urothelial carcinoma (UC). Methods: We used AACR GENIE, The Cancer Genome Atlas, International Cancer Genome Consortium, several public databases related to immune therapy, chemotherapy, and BCG treatment. We studied the gender-biased prognostic role of KDM6A mutation in several cohorts and the association between KDM6A mutation and immune-related fractions according to gender. Results: The expression of KDM6A was higher in females than in males in several cohorts. Mutation of KDM6A was observed in about 20–25% of the patients. The rate of KDM6A mutation was higher in females than in males in several cohorts. Kaplan–Meier analysis revealed a gender-biased difference in prognosis between patients with KDM6A mutations and those with the wild-type KDM6A in several cohorts, including the immune therapy cohort. The rate of immune-inflamed type was higher in males than in females in the patients with KDM6A mutation in the IMvigor 210 and UC-GENOME studies. Single-sample Gene Set Enrichment Analysis showed that CD8+ cells and type 1 IFN response fractions and APC co-inhibition fraction were higher in the male than female patients with KDM6A mutation. Similar findings were observed in other immune-related studies (UC-GENOME). Conclusions: The effect of KDM6A mutation on immune therapy varied according to gender, and the status of KDM6A mutation may be a promising biomarker in immune therapy in UC.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K18586)
This publication has 45 references indexed in Scilit:
- Genomic heterogeneity as a barrier to precision oncology in urothelial cancerCell Reports, 2022
- MAGE‐C3 promotes cancer metastasis by inducing epithelial‐mesenchymal transition and immunosuppression in esophageal squamous cell carcinomaCancer Communications, 2021
- Molecular classification and diagnostics of upper urinary tract urothelial carcinomaCancer Cell, 2021
- Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesEuropean Urology Oncology, 2020
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEuropean Urology, 2017
- Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation FrequencyCancer Cell, 2017
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Enigmatic sex disparities in cancer incidenceEuropean Journal of Epidemiology, 2012
- Association Between Smoking and Risk of Bladder Cancer Among Men and WomenJAMA, 2011
- The effect of smoking on the male excess of bladder cancer: A meta‐analysis and geographical analysesInternational Journal of Cancer, 2008